Wave Life Sciences (WVE) news
Recent news
Wave Life Sciences - WVE-006 continues to be generally safe and well tolerated with no liver toxicities
AInvest Wire · Oct 1, 2026Wave Life Sciences - Plans two-year registration trial with one-year interim analysis for accelerated approval
AInvest Wire · Oct 1, 2026Wave Life: Eligible for up to $330M-$375M per GSK program
Wave Life Sciences (NASDAQ: WVE) has disclosed potential milestone payments of up to $330 million to $375 million per program under its collaboration with GlaxoSmithKline (GSK). These figures represent the maximum possible payments Wave could receive based on the terms of the partnership, which…
AInvest Wire · Sep 30, 2026Wave Life Sciences: GSK's candidate uses Spina design siRNA
AInvest Wire · Sep 30, 2026Wave Life Sciences to get $12M GSK milestone payment
Wave Life Sciences is set to receive a $12 million milestone payment from GlaxoSmithKline (GSK) as part of their ongoing collaboration in the development of RNA-based therapeutics. The payment is tied to the achievement of specific developmental and regulatory milestones under the terms of their…
AInvest Wire · Sep 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.